The University of California, University of Vienna, and researcher Emmanuelle Charpentier, as well as their commercial partners, are linked by the agreement.
After CRISPR/Cas9 makes a double-strand break in DNA and the cell repairs it, the same set of mutations crop up again and again based on the genomic sequence.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
Caribou will license its CRISPR technology to Genus to help it create pigs that are resistant to Porcine Reproductive and Respiratory Syndrome Virus.
The financing round includes new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech.
The Berkeley, California-based company is aiming to turn CRISPR into a platform technology for clinical and industrial applications.
The USPTO has become involved in the CRISPR-Cas9 patent dispute.
As the interference proceeding to resolve claims in foundational CRISPR patents draws near, Caribou has given IDT worldwide rights to sell RUO reagents.
In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.
Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.
HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.
Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.